S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:IPSC

Century Therapeutics - IPSC Stock Forecast, Price & News

$10.56
+0.06 (+0.57%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.22
$10.63
50-Day Range
$9.32
$11.58
52-Week Range
$7.32
$19.39
Volume
46,213 shs
Average Volume
92,090 shs
Market Capitalization
$622.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.33

Century Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
139.9% Upside
$25.33 Price Target
Short Interest
Bearish
9.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.90mentions of Century Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.33) to ($2.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

752nd out of 1,047 stocks

Biological Products, Except Diagnostic Industry

123rd out of 173 stocks

IPSC stock logo

About Century Therapeutics (NASDAQ:IPSC) Stock

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IPSC Stock News Headlines

Century Therapeutics joins Russell Microcap® Index
See More Headlines
Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IPSC Company Calendar

Last Earnings
11/10/2021
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IPSC
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.33
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+139.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-95,820,000.00
Pretax Margin
-2,722.15%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.60 per share

Miscellaneous

Free Float
52,900,000
Market Cap
$622.72 million
Optionable
Not Optionable
Beta
0.41

Key Executives

  • Dr. Osvaldo  Flores Ph.D.Dr. Osvaldo Flores Ph.D. (Age 59)
    Pres, CEO & Director
    Comp: $778.06k
  • Dr. Adrienne Farid Ph.D. (Age 60)
    Chief Operations Officer
    Comp: $589.47k
  • Dr. Luis Borges (Age 60)
    Chief Scientific Officer
    Comp: $604.12k
  • Mr. Douglas Carr CPA
    VP of Fin. and Operations & Sec.
  • Dr. Gregory Russotti Ph.D. (Age 55)
    Chief Technology Officer
  • Mr. Kenneth J. Dow J.D.
    Head of Legal & Compliance
  • Dr. Shane Williams Ph.D.
    Chief People Officer
  • Dr. Michael C. Diem (Age 51)
    Chief Bus. Officer
  • Dr. Hyam I. Levitsky M.D. (Age 64)
    Pres of R&D
  • Mr. Mark Wallet
    Head of Immunology & VP













IPSC Stock - Frequently Asked Questions

Should I buy or sell Century Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IPSC shares.
View IPSC analyst ratings
or view top-rated stocks.

What is Century Therapeutics' stock price forecast for 2023?

8 brokerages have issued twelve-month target prices for Century Therapeutics' shares. Their IPSC share price forecasts range from $15.00 to $32.00. On average, they expect the company's stock price to reach $25.33 in the next year. This suggests a possible upside of 139.9% from the stock's current price.
View analysts price targets for IPSC
or view top-rated stocks among Wall Street analysts.

How have IPSC shares performed in 2022?

Century Therapeutics' stock was trading at $15.86 at the beginning of 2022. Since then, IPSC stock has decreased by 33.4% and is now trading at $10.56.
View the best growth stocks for 2022 here
.

When is Century Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our IPSC earnings forecast
.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.08.

When did Century Therapeutics IPO?

(IPSC) raised $201 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Century Therapeutics' stock symbol?

Century Therapeutics trades on the NASDAQ under the ticker symbol "IPSC."

Who are Century Therapeutics' major shareholders?

Century Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.39%), Vanguard Group Inc. (1.81%), Logos Global Management LP (0.78%), State Street Corp (0.55%), Point72 Asset Management L.P. (0.28%) and Bank of New York Mellon Corp (0.10%). Insiders that own company stock include Eli Casdin and Versant Venture Capital Vi, L.
View institutional ownership trends
.

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Century Therapeutics' stock price today?

One share of IPSC stock can currently be purchased for approximately $10.56.

How much money does Century Therapeutics make?

Century Therapeutics (NASDAQ:IPSC) has a market capitalization of $622.77 million. The company earns $-95,820,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

How many employees does Century Therapeutics have?

The company employs 170 workers across the globe.

How can I contact Century Therapeutics?

The official website for the company is www.centurytx.com. The company can be reached via phone at 267-817-5790 or via email at investor.relations@centurytx.com.

This page (NASDAQ:IPSC) was last updated on 12/2/2022 by MarketBeat.com Staff